Gisèle N'Kontchou, Amel Mahamoudi, Mounir Aout, Nathalie Ganne‐Carrié, Véronique Grando, Emmanuelle Coderc, Eric Vicaut, Jean Claude Trinchet, Nicolas Sellier, Michel Beaugrand, Olivier Seror – 29 October 2009 – For the treatment of small hepatocellular carcinoma (HCC), radiofrequency ablation (RFA) is in some centers considered a first‐line therapeutic option. However, such a strategy is still under debate with regard to tumor and patient characteristics.

Stéphane Chevaliez, Jenna Fix, Alexandre Soulier, Jean‐Michel Pawlotsky – 29 October 2009

Xinchao Pan, Xunde Wang, Weiwei Lei, Lihua Min, Yanan Yang, Xin Wang, Jianguo Song – 29 October 2009 – Nitric oxide (NO) is a multifunctional regulator that is implicated in various physiological and pathological processes. Here we report that administration of NO donor S‐nitroso‐N‐acetylpenicillamine (SNAP) inhibited transforming growth factor‐β1 (TGF‐β1)‐induced epithelial‐to‐mesenchymal transition (EMT) and apoptosis in mouse hepatocytes.

Iris Sawitza, Claus Kordes, Sven Reister, Dieter Häussinger – 29 October 2009 – It is well‐accepted that hepatic stellate cells (HSCs) can develop into myofibroblast‐like cells that synthesize extracellular matrix proteins and contribute to liver fibrosis. Recently, molecular markers of stem/progenitor cells were discovered in HSCs of rats. Moreover, the cells displayed the capacity to differentiate and to participate in liver regeneration.

Gakuhei Son, Ian N. Hines, Jeff Lindquist, Laura W. Schrum, Richard A. Rippe – 29 October 2009 – The hepatic stellate cell (HSC) is the primary cell type in the liver responsible for excess collagen deposition during fibrosis. Following a fibrogenic stimulus the cell changes from a quiescent vitamin A–storing cell to an activated cell type associated with increased extracellular matrix synthesis and increased cell proliferation.

Gideon M. Hirschfield, Katherine A. Siminovitch – 29 October 2009

Toshihiko Ikegami, Yuichi Masuda, Yasunari Ohno, Atsushi Mita, Akira Kobayashi, Koichi Urata, Yuichi Nakazawa, Shirou Miwa, Yasuhiko Hashikura, Shinichi Miyagawa – 28 October 2009 – We have previously reported that a graft volume (GV) > 30% of the recipient's standard liver volume (SLV) can meet the recipient's metabolic demands. Here we report our experience with adult‐to‐adult living donor liver transplantation using left side grafts < 35% of the recipient's SLV.

Avnish Kumar Seth, Pradhi Nambiar, Ajay Joshi, Ramanathan Ramprasad, Rajendra Choubey, Pankaj Puri, Mandapaka Murthy, Sudeep Naidu, Anupam Saha, Harjinder Bhatoe – 28 October 2009 – Organ donation following brain stem death is infrequent in India. There is no prospective study on prevalence of brain stem death and causes of non‐donation. Consecutive patients admitted to intensive care unit from Sep 2006 to Sep 2008 were studied prospectively. Families of those with brain stem death were approached for organ donation by transplant coordinator. Extensive awareness drive was launched.

Seong H. Ra, Jeffrey B. Kaplan, Charles R. Lassman – 28 October 2009 – Focal nodular hyperplasia (FNH) has been well characterized in native livers, but to our knowledge, no cases of FNH have been described in liver allografts. We review the clinicopathological features of 6 FNHs identified in 4 patients after orthotopic liver transplantation. There were 3 male patients and 1 female patient ranging in age from 2 to 63 years. The time from transplant to a diagnosis of FNH ranged from 15 to 118 months. Two patients presented with an incidental solitary liver nodule.

Alejandra Otero, Evaristo Varo, Jorge Ortiz de Urbina, Rafael Martín‐Vivaldi, Valentin Cuervas‐Mons, Ignacio González‐Pinto, Antoni Rimola, Angel Bernardos, Santiago Otero, Jorge Maldonado, Jose I. Herrero, Elena Barrao, Rosa Domínguez‐Granados – 28 October 2009 – This open‐label, randomized study compared the efficacy of a regimen of corticosteroids and tacrolimus (standard therapy group, n = 79) with a regimen of daclizumab induction therapy in combination with mycophenolate mofetil and tacrolimus (modified therapy group, n = 78) in primary liver transplant recipients.